Design, Optimization, and Evaluation of Resveratrol Based Nanostructured Lipid Carriers for Enhanced Antidiabetic Efficacy

Abstract

Aim:  To design, optimize and evaluate Resveratrol-loaded Nanostructured Lipid Carriers (NLCs) for improved drug delivery, sustained release, and enhanced therapeutic efficacy in the treatment of diabetes mellitus.

Objective: To overcome the limitations of conventional antidiabetic therapies by formulating optimized Resveratrol-loaded NLCs and evaluating their physicochemical properties, drug content, entrapment efficiency, and in vitro drug release profile.

Method:  Resveratrol-loaded  NLCs  were  prepared  by  the  high-speed  homogenization  method  using  varying  concentrations  of lipids, and surfactants. The formulations were characterized for particle size, zeta potential, drug  content, and  entrapment efficiency.  FTIR  and  DSC  analysis  were  performed  to  assess drug–excipient  compatibility. In  vitro drug release(diffusion)studies were conducted to evaluate drug release behavior.

Result: FTIR  and  DSC  studies  confirmed  the  absence  of  drug–excipient  incompatibility.  The  optimized  formulation  (RF4) showed a particle size of 196.2nm, drug content of 97.26%,and entrapment efficiency of 94.29%.The in  vitro drug release profile indicated sustained drug release, and stability studies confirmed excellent physical stability as per ICH guidelines.

Conclusion: Resveratrol-loaded NLCs demonstrated sustained release, high stability, and superior drug encapsulation, indicating strong potential as an effective and stable nanocarrier system for the management of diabetes mellitus